KOL Pulse AI· @KolPulseAI · X·· 20 hours agoScore70
Body
"Author concludes “modest” benefit; I would say “disappointing”." @DrSGraff
#ESMO26 TALENT: neoadjuvant T-DXd alone, with anastrozole or before TC in HR+/HER2-low early breast cancer. pCR 7%, 3% and 9%. Investigational. @DaiichiSankyoUS
https://hubs.ly/Q04CdhhS0
7 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA23matched by Proffered paper 1: Breast cancer, early and advanced stage
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.orgSource: KOL Pulse AI · x.com